Lilly agrees to acquire AtaiBeckley for about $2.8 billion upfront

Eli Lilly and Company said on July 16, 2026 that it had agreed to acquire AtaiBeckley Inc., a clinical-stage biotech developing rapid-acting mental health drugs, in a deal worth about $2.8 billion upfront ^[1]. The transaction closed on September 11, 2026, after AtaiBeckley shareholders approved it at a special meeting ^[2].

Under the agreement, Lilly is paying $6.75 per share in cash at closing, plus up to $2.50 per share more through a contingent value right, or CVR, tied to future drug approvals ^[1]. The upfront cash totals roughly $2.8 billion in equity value, and the CVR could add up to about $1.0 billion more if certain milestones are met ^[1]. The cash price represented about a 40% premium over AtaiBeckley's 30-day average trading price through July 15, 2026 ^[1].

AtaiBeckley's lead program is BPL-003, an intranasal synthetic form of 5-MeO-DMT being studied for treatment-resistant depression, a condition that persists after standard treatments fail ^[1]. In a Phase 2b study, a single in-clinic session lasting about two hours produced reductions in depressive symptoms that lasted for months, according to Lilly ^[1]. The FDA has granted BPL-003 Breakthrough Therapy Designation, and the drug has begun Phase 3 activities ^[1]. A second program, VLS-01, is a buccal film form of DMT in an ongoing Phase 2b study, and a third, EMP-01, is a form of MDMA being tested for social anxiety disorder in Phase 2 ^[1][2].

The CVR payments are tied to specific dates: $1.00 per share if a Phase 3 trial of VLS-01 starts within four years of closing, $0.50 per share if BPL-003 wins U.S. approval and DEA rescheduling within five years, and $1.00 per share if VLS-01 wins U.S. approval and DEA rescheduling within seven years ^[1]. Lilly noted there is no guarantee any of these CVR payments will ever be made ^[1].

Carole Ho, president of Lilly Neuroscience, said treatment-resistant depression leaves millions of people still searching for relief, and called AtaiBeckley's neuroplastogens a potential new treatment paradigm that moves away from chronic daily dosing ^[2]. AtaiBeckley chief executive Srinivas Rao said the goal is to treat psychiatric illness at its biological root rather than just its symptoms ^[1].

Why it matters for patients

This deal is about Lilly's mental health pipeline, not about semaglutide or tirzepatide products such as Zepbound, Mounjaro, Ozempic, or Wegovy. Nothing in the announcements changes the price, availability, or approved use of any current GLP-1 medicine ^[1][2].

For people already taking or considering a GLP-1 drug, the practical relevance is indirect. It shows Lilly, the maker of Zepbound and Mounjaro, is spending billions to expand beyond diabetes and obesity into psychiatric drug development, using a company structure, molecule types, and regulatory pathway that are entirely different from GLP-1 therapies ^[1]. BPL-003 and VLS-01 are not weight-loss or diabetes drugs, and they involve DEA-controlled substances that require scheduling changes before they could reach patients ^[1].

What the acquisition does not do is establish any near-term connection between GLP-1 treatment and these psychedelic-based therapies. Anyone tracking Lilly's broader business, including its finances and future drug lineup, may find this relevant context, but it is not yet known whether or how these programs might intersect with obesity or diabetes care down the road, since none of the sources address that question ^[1][2].

What happens next

BPL-003 has entered Phase 3 activities, and its CVR milestone for U.S. approval and DEA rescheduling is set for within five years of the September 11, 2026 closing ^[1][2]. VLS-01 remains in Phase 2b, with a CVR milestone for starting a Phase 3 trial within four years, and a further milestone for its own U.S. approval and DEA rescheduling within seven years ^[1]. EMP-01, for social anxiety disorder, is in Phase 2 development, with no milestone dates disclosed ^[1][2].